Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 28.99% is 17% above its 5-year average of 24.69%, around the middle of its 5-year range (12.99%–53.01%).
As of the fiscal period ended Tuesday, June 30, 2026. 31.83% above its 12-month average of 21.99%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 28.99%.
DEBT TO ASSETS RATIO
28.99%
DEBT TO ASSETS RATIO AVG TTM
21.99%
DEBT TO ASSETS RATIO AVG 3Y
24.74%
DEBT TO ASSETS RATIO AVG 5Y
24.69%
DEBT TO ASSETS RATIO AVG 10Y
24.16%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+31.83%
CURRENT VS 3Y AVG
+17.15%
CURRENT VS 5Y AVG
+17.42%
CURRENT VS 10Y AVG
+19.98%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 836 covered companies
CURRENT VS SECTOR MEDIAN
+32110.67%
vs the sector median at left
Aptevo Therapeutics Inc.
Market Cap
$3.97M
Debt to Assets Ratio
28.99%
TTM Avg
21.99%
3Y Avg
24.74%
5Y Avg
24.69%
Market Cap
$4.01M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.04M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.13M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.34M
Debt to Assets Ratio
0.37%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | $3.97M | 28.99% | 21.99% | 24.74% | 24.69% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.01M | 0.06% | N/A | N/A | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.04M | 0.00% | N/A | N/A | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $4.13M | 0.04% | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.15M | 0.00% | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.71M | 0.16% | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.25M | 0.09% | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | 0.37% | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.58M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.53M | 0.00% | N/A | N/A | N/A |
Debt/Assets
29.0%
Debt/Equity
0.70
Current Ratio
2.08
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 28.99% |
| 2026-03-31 | 22.22% |
| 2025-12-31 | 17.02% |
| 2025-09-30 | 14.78% |
| 2025-06-30 | 26.94% |
| 2025-03-31 | 53.01% |
| 2024-12-31 | 29.69% |
| 2024-09-30 | 31.89% |
| 2024-06-30 | 33.68% |
| 2024-03-31 | 29.58% |
| 2023-12-31 | 21.73% |
| 2023-09-30 | 20.55% |
| 2023-06-30 | 19.88% |
| 2023-03-31 | 16.92% |
| 2022-12-31 | 27.87% |
| 2022-09-30 | 32.01% |
| 2022-06-30 | 27.70% |
| 2022-03-31 | 12.99% |
| 2021-12-31 | 29.53% |
| 2021-09-30 | 26.23% |
| 2021-06-30 | 23.59% |
| 2021-03-31 | 24.58% |
| 2020-12-31 | 51.20% |
| 2020-09-30 | 74.29% |
| 2020-06-30 | 15.44% |
| 2020-03-31 | 12.28% |
| 2019-12-31 | 43.42% |
| 2019-09-30 | 38.40% |
| 2019-06-30 | 35.26% |
| 2019-03-31 | 28.96% |
| 2018-12-31 | 28.56% |
| 2018-09-30 | 24.25% |
| 2018-06-30 | 21.74% |
| 2018-03-31 | 19.27% |
| 2017-12-31 | 16.29% |
| 2017-09-30 | 13.34% |
| 2017-06-30 | 21.57% |
| 2017-03-31 | 18.85% |
| 2016-12-31 | 20.01% |
| 2016-09-30 | 18.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
